NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating potent anti-tumor ...
Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in ...
Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type ...
Nurix on Monday said the FDA granted orphan-drug designation to bexobrutideg, also known as NX-5948, for the treatment of Waldenstrom macroglobulinemia, a slow growing type of non-Hodgkin's lymphoma ...
Nurix Therapeutics (NRIX) announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to bexobrutideg, ...
First-in-class Bruton's tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name "bexobrutideg” in newly named ...
WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of ...
Nurix Therapeutics (NRIX)’ treatment of Waldenstrom macroglobulinemia was granted FDA orphan designation, according to a post on the agency’s website. Published first on TheFly – the ...
David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today. David A. Russler-Germain, MD, PhD, physician-scientist at Washington ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback